Your browser is no longer supported. Please, upgrade your browser.
PGNX Progenics Pharmaceuticals, Inc. daily Stock Chart
Progenics Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.85 Insider Own0.20% Shs Outstand87.59M Perf Week-5.67%
Market Cap437.07M Forward P/E- EPS next Y-0.74 Insider Trans492.13% Shs Float77.90M Perf Month-16.42%
Income-72.00M PEG- EPS next Q-0.22 Inst Own78.70% Short Float7.84% Perf Quarter3.10%
Sales23.10M P/S18.92 EPS this Y-11.60% Inst Trans1.73% Short Ratio5.27 Perf Half Y16.86%
Book/sh0.65 P/B7.68 EPS next Y21.30% ROA-46.70% Target Price9.30 Perf Year7.54%
Cash/sh0.74 P/C6.78 EPS next 5Y- ROE-92.00% 52W Range3.42 - 6.31 Perf YTD18.81%
Dividend- P/FCF- EPS past 5Y-2.60% ROI-44.40% 52W High-18.78% Beta2.67
Dividend %- Quick Ratio3.80 Sales past 5Y14.70% Gross Margin92.20% 52W Low49.85% ATR0.21
Employees79 Current Ratio3.80 Sales Q/Q5.70% Oper. Margin- RSI (14)44.25 Volatility3.07% 4.13%
OptionableYes Debt/Eq0.73 EPS Q/Q28.10% Profit Margin- Rel Volume0.33 Prev Close4.99
ShortableYes LT Debt/Eq0.62 EarningsNov 14 BMO Payout- Avg Volume1.16M Price5.13
Recom1.70 SMA20-6.38% SMA50-3.77% SMA2003.80% Volume360,532 Change2.71%
Dec-07-18Initiated Credit Suisse Outperform $6.50
Sep-14-18Downgrade Needham Strong Buy → Buy $16 → $12
Aug-01-18Reiterated Needham Strong Buy $14 → $16
Feb-06-17Upgrade Needham Buy → Strong Buy $11 → $14
Oct-27-16Initiated Aegis Capital Buy
Oct-23-15Upgrade Jefferies Hold → Buy
Aug-07-15Reiterated Needham Buy $9 → $11
Aug-06-15Reiterated Brean Capital Buy $11 → $14
Feb-03-14Upgrade Needham Hold → Buy $8
Aug-30-12Initiated Stifel Nicolaus Hold
Jul-30-12Downgrade Needham Buy → Hold
Feb-10-11Upgrade Brean Murray Hold → Buy $13
Oct-14-09Downgrade Needham Buy → Hold
May-12-09Reiterated RBC Capital Mkts Outperform $14 → $12
Mar-16-09Reiterated RBC Capital Mkts Outperform $21 → $14
Mar-16-09Downgrade Oppenheimer Outperform → Perform
Mar-16-09Downgrade Brean Murray Buy → Hold
Mar-12-09Initiated FTN Equity Capital Neutral
Aug-11-08Reiterated RBC Capital Mkts Outperform $19 → $21
Jul-02-08Downgrade Friedman Billings Mkt Perform → Underperform $9 → $12
Dec-04-19 08:00AM  INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders AMTD, TIF, MDCO, PGNX GlobeNewswire
Nov-25-19 08:30AM  Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting GlobeNewswire
Nov-21-19 04:05PM  Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer GlobeNewswire
Nov-08-19 04:05PM  Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections GlobeNewswire
02:21PM  Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board Business Wire
Nov-07-19 11:45AM  Progenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates Zacks
10:30AM  Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for Zacks
08:00AM  Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results GlobeNewswire
Nov-06-19 08:00AM  Progenics Reminds Shareholders that November 17 is the True Deadline for Velans Consent Solicitation GlobeNewswire
Nov-04-19 08:00AM  Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velans Nominees Control of the Board GlobeNewswire
08:00AM  Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board Business Wire
Nov-02-19 09:20AM  ACT NOW: Monteverde & Associates PC Continues Legal Inquiry Regarding the Merger ACCESSWIRE
Nov-01-19 01:00PM  Progenics Reminds Shareholders that November 17 is the Only Deadline for Velans Consent Solicitation GlobeNewswire +6.21%
Oct-30-19 08:23PM  Progenics Pharmaceuticals, Inc. (PGNX) Is Burning These Hedge Funds Insider Monkey
Oct-28-19 02:00PM  Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors GlobeNewswire
07:00AM  ISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEO Business Wire
Oct-24-19 02:05PM  Independent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders Business Wire
07:36AM  The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise Benzinga
Oct-23-19 05:03PM  Velan Responds to Misleading Communications from Progenics Business Wire
09:55AM  Progenics Highlights Additional Serious Concerns About Velan Capital, L.P. GlobeNewswire
Oct-22-19 09:00AM  Velan Sends Letter to Progenics Stockholders Business Wire
Oct-21-19 08:46AM  Progenics Sends Letter to Shareholders GlobeNewswire
08:00AM  Velan Issues Presentation Outlining Nominees Comprehensive Strategic Plan to Save Progenics Business Wire
Oct-18-19 12:00PM  SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders - PRTO, ROAN, PGNX ACCESSWIRE
Oct-17-19 01:58PM  PGNX, PRTO, and ARTX SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire
Oct-15-19 10:12AM  Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders RARX, PGNX, TSG, ROAN GlobeNewswire
Oct-11-19 03:20PM  Progenics Pharmaceuticals Needs a Treatment for Sickly Corporate Governance
06:57AM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) ACCESSWIRE
Oct-10-19 03:10PM  INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Acquisition ACCESSWIRE
Oct-09-19 04:30PM  Progenics Sends Letter to Shareholders GlobeNewswire
Oct-08-19 04:11PM  SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, PGNX, DOVA Shareholders About Its Ongoing Investigations GlobeNewswire -5.23%
03:55PM  Lifshitz & Miller LLP Announces Investigation of Arotech Corporation, Dova Pharmaceuticals, Inc., Highlands Bankshares, Inc., Progenics Pharmaceuticals, Inc., Proteon Therapeutics, Inc., Roan Resources, Inc., SemGroup Corporation and The Stars Group Inc. PR Newswire
08:00AM  Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement Business Wire
Oct-04-19 06:14PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc. PR Newswire
07:30AM  Possible M&A Surrounds These 3 Stocks
Oct-03-19 05:50PM  PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX Business Wire
03:54PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigations of Mergers GlobeNewswire
12:14PM  INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of the Following Merger PR Newswire
11:26AM  Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Progenics Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Lantheus Holdings, Inc. PR Newswire
10:52AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Progenics Pharmaceuticals, Inc. to Lantheus Holdings, Inc. is Fair to Shareholders GlobeNewswire
06:44AM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) ACCESSWIRE
Oct-02-19 05:04PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on Behalf of Progenics Shareholders and Encourages Progenics Investors to Contact the Firm PR Newswire +11.11%
03:12PM  Lantheus To Acquire Progenics Pharma In All-Stock Deal Benzinga
02:25PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Progenics Pharmaceuticals, Inc. PR Newswire
01:23PM  Velan Comments on Announced Sale of Progenics to Lantheus Business Wire
11:45AM  PROGENICS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Merger ACCESSWIRE
11:17AM  Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm PGNX GlobeNewswire
08:33AM  Progenics's stock drops after all-stock buyout deal, as acquirer Lantheus's shares plunge MarketWatch
07:08AM  Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company Business Wire
05:38AM  Lantheus Acquires Progenics in All-Stock Deal, Both Companies Drop in Trading
Sep-27-19 08:00PM  Beacon Roofing, Sunrun, Marchex and Other 13D Filings
Sep-18-19 04:59PM  Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution GlobeNewswire
08:55AM  Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees Business Wire
Sep-09-19 06:00AM  These 2 Biotech Stocks Are Seeing Insider Buying Activity
Sep-03-19 08:30AM  Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations GlobeNewswire
Aug-30-19 09:00PM  Dynavax, Fastly, PulteGroup, and Other 13D Filings
Aug-23-19 10:59AM  Progenics Investors Seek Changes at the Top as Activist Gains Traction Bloomberg
Aug-15-19 10:25AM  Edited Transcript of PGNX earnings conference call or presentation 9-Aug-19 12:30pm GMT Thomson Reuters StreetEvents -5.26%
Aug-12-19 08:00AM  Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results PR Newswire -16.13%
Aug-09-19 11:23PM  Progenics Pharmaceuticals (PGNX) Q2 2019 Earnings Call Transcript Motley Fool -6.06%
10:23AM  Could The Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ownership Structure Tell Us Something Useful? Simply Wall St.
08:55AM  Progenics (PGNX) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM  Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Aug-08-19 08:00AM  Progenics Pharmaceuticals Announces Additional Governance Enhancements GlobeNewswire
Aug-06-19 08:30AM  CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131) GlobeNewswire
Aug-05-19 08:30AM  Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer GlobeNewswire
Aug-01-19 08:30AM  Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9 GlobeNewswire
Jul-25-19 08:30AM  Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis GlobeNewswire
Jul-22-19 08:00AM  Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting PR Newswire
Jul-17-19 07:41PM  Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets CNW Group
Jul-12-19 09:11AM  Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders GlobeNewswire
Jul-08-19 08:30AM  Progenics Urges Shareholders to Vote Today FOR the Highly Qualified Director Candidates on the WHITE Proxy Card GlobeNewswire
08:00AM  Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch PR Newswire
07:30AM  Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial GlobeNewswire
Jul-05-19 12:26PM  Heres What Hedge Funds Think About Progenics Pharmaceuticals, Inc. (PGNX) Insider Monkey
Jul-01-19 08:00AM  Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch PR Newswire
07:00AM  Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote FOR ALL of Progenics Director Nominees GlobeNewswire
Jun-28-19 11:40AM  ISS Supports Velan's Call for Change by Recommending Stockholders Vote "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch PR Newswire +6.01%
10:30AM  Progenics Reiterates Targeted Directors Indispensable Experience and Leadership Critical to the Companys Long-Term Success GlobeNewswire
07:32AM  The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO Benzinga
12:01AM  Velan Clarifies Interactions with Progenics Pharmaceuticals' Board of Directors PR Newswire
Jun-27-19 09:00PM  Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital GlobeNewswire +5.82%
Jun-25-19 08:30AM  Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer GlobeNewswire
08:29AM  Velan Releases Presentation Reiterating the Facts and Setting The Record Straight for Progenics Pharmaceuticals' Stockholders PR Newswire
Jun-24-19 08:30AM  Independent Readers Using Progenics PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI GlobeNewswire
08:00AM  Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velans Latest Inaccurate Claims GlobeNewswire
Jun-20-19 05:21PM  Velan Releases Detailed Presentation on Progenics Pharmaceuticals PR Newswire
08:30AM  Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors GlobeNewswire
07:30AM  Velan Calls on Progenics Pharmaceuticals' Board to Back Up Recent Claims PR Newswire
Jun-19-19 12:05PM  Did Changing Sentiment Drive Progenics Pharmaceuticals's (NASDAQ:PGNX) Share Price Down By 46%? Simply Wall St.
08:30AM  Progenics to Mail Letter to Shareholders GlobeNewswire
Jun-18-19 09:05AM  Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan GlobeNewswire +6.41%
Jun-17-19 08:30AM  Velan sets the Record Straight on Progenics Pharmaceuticals' Latest Misleading Statements PR Newswire +6.85%
Jun-13-19 05:00PM  Progenics to Mail Letter to Shareholders GlobeNewswire
08:30AM  Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer GlobeNewswire
Jun-11-19 08:30AM  Velan Capital Sends Letter to Stockholders Calling Out Progenics Pharmaceuticals' Board for Unnecessarily Diluting Stockholders to Support Outsized And Undeserved Compensation PR Newswire
Jun-06-19 07:45AM  Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting GlobeNewswire
Jun-04-19 08:30AM  Velan Responds to Progenics Pharmaceuticals' Misleading Statements PR Newswire +6.85%
Jun-03-19 08:30AM  Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma GlobeNewswire
08:00AM  Progenics Pharmaceuticals Mails Letter to Shareholders GlobeNewswire
Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Velan Capital, L.P.See Explanation of ResponsesSep 09Buy4.9972,023359,7338,011,733Sep 11 01:32 PM
LTE Partners, LLCSee Explanation of ResponsesSep 09Buy4.9421,480106,0961,950,000Sep 09 06:14 PM
LTE Partners, LLCSee Explanation of ResponsesSep 05Buy4.6243,520201,0971,928,520Sep 09 06:14 PM
Velan Capital, L.P.See Explanation of ResponsesSep 04Buy4.51243,6141,098,5297,939,710Sep 05 04:37 PM
Velan Capital, L.P.See Explanation of ResponsesSep 03Buy4.39277,4241,218,9187,696,096Sep 05 04:37 PM
Velan Capital, L.P.See Explanation of ResponsesAug 26Buy4.3073,230314,9117,418,672Aug 27 03:45 PM
Velan Capital, L.P.See Explanation of ResponsesAug 23Buy4.31130,826563,6907,345,442Aug 27 03:45 PM
Campbell Bradley LDirectorJul 03Option Exercise4.8912,00058,68012,000Jul 08 12:32 PM
SCHEINBERG DAVID ADirectorJul 01Option Exercise5.3310,00053,30056,185Jul 03 08:56 AM
Crowley Peter JDirectorJun 26Option Exercise5.3550,000267,30050,000Jun 27 04:33 PM